License and Development Agreements (Details) - USD ($) $ in Thousands		1 Months Ended			12 Months Ended
	Sep. 30, 2025	Oct. 31, 2023	Jan. 31, 2023	Sep. 30, 2022	Dec. 31, 2025	Dec. 31, 2024
Disaggregation of Revenue [Line Items]
Total revenue					$ 4,413	$ 4,055
Expense incurred					39,750	32,126
Initial non-refundable fee	$ 800
Upfront payment	$ 800
Deferred revenue					800
NIAID Project NextGen clinical trial initiative		$ 5,000,000
Initial license issuance fee				$ 1,000
Required annual license maintenance fee			$ 100
Aggregate payment amount of annual development and commercial milestones			$ 37,000
Cancellation period, notice			90 days
Collaborative Arrangements
Disaggregation of Revenue [Line Items]
Total revenue					4,413	4,055
Expense incurred					2,000	1,900
Contract liability					5,907	8,368
Exclusive License Agreement with SERI
Disaggregation of Revenue [Line Items]
Annual maintenance payments					25	75
Milestone payments						750
Exclusive License Agreement with the CU
Disaggregation of Revenue [Line Items]
Annual maintenance payments					$ 20	$ 20